Journal of thrombosis and haemostasis : JTH · 2026
Teclistamab for the treatment of autoantibody-mediated coagulation disorders.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thaler Johannes, Gleixner Karoline, Eischer Lisbeth, Kammerer Gabriel, Rettl Joachim, Sailer Lisa, Sillaber Christian, Quehenberger Peter, Krauth Maria Theresa, Knöbl Paul, Ay Cihan, Agis Hermine
Аннотация
BACKGROUND: Teclistamab is a bispecific monoclonal antibody that targets B cell maturation antigen (BCMA) on plasma cells and other B lineage cells and CD3 on T cells, thereby redirecting cytotoxic T cells to eliminate BCMA-expressing antibody-producing cells. Autoantibody-mediated coagulation disorders are often driven by long-lived antibody-producing cells that may persist despite conventional immunosuppression or B cell depletion.
OBJECTIVE: To investigate whether teclistamab represents a treatment option for patients with refractory or rapidly progressive autoantibody-mediated coagulation disorders.
METHODS: We retrospectively analyzed seven patients with autoantibody-mediated coagulation disorders treated with teclistamab. Diagnoses included acquired von Willebrand disease (n=2), acquired factor XI deficiency (n=2), and catastrophic antiphospholipid syndrome (CAPS; n=3). Five patients had an underlying paraprotein, whereas two CAPS patients had no detectable paraprotein.
RESULTS: All seven patients achieved complete remissions (median time to remission: 24 weeks [range: 2-35]) following teclistamab. In the four patients with acquired von Willebrand disease or factor XI deficiency, improvement in the disease-defining coagulation parameter and cessation of bleeding were observed following initiation of teclistamab. In the three patients with CAPS disappearance of antiphospholipid antibodies or normalization of the aPTT-LA was observed and accompanied by clinical stabilization without further thromboembolic events. Treatment was generally well tolerated. Three patients developed grade 1 cytokine release syndrome. One patient developed transient colitis while another patient experienced reversible seronegative inflammatory joint symptoms. All patients received immunoglobulin replacement.
CONCLUSION: Teclistamab treatment was associated with complete remissions in patients with autoantibody-mediated coagulation disorders. These observations warrant further evaluation of teclistamab in selected patients.
OBJECTIVE: To investigate whether teclistamab represents a treatment option for patients with refractory or rapidly progressive autoantibody-mediated coagulation disorders.
METHODS: We retrospectively analyzed seven patients with autoantibody-mediated coagulation disorders treated with teclistamab. Diagnoses included acquired von Willebrand disease (n=2), acquired factor XI deficiency (n=2), and catastrophic antiphospholipid syndrome (CAPS; n=3). Five patients had an underlying paraprotein, whereas two CAPS patients had no detectable paraprotein.
RESULTS: All seven patients achieved complete remissions (median time to remission: 24 weeks [range: 2-35]) following teclistamab. In the four patients with acquired von Willebrand disease or factor XI deficiency, improvement in the disease-defining coagulation parameter and cessation of bleeding were observed following initiation of teclistamab. In the three patients with CAPS disappearance of antiphospholipid antibodies or normalization of the aPTT-LA was observed and accompanied by clinical stabilization without further thromboembolic events. Treatment was generally well tolerated. Three patients developed grade 1 cytokine release syndrome. One patient developed transient colitis while another patient experienced reversible seronegative inflammatory joint symptoms. All patients received immunoglobulin replacement.
CONCLUSION: Teclistamab treatment was associated with complete remissions in patients with autoantibody-mediated coagulation disorders. These observations warrant further evaluation of teclistamab in selected patients.